GBIM.US GlobeImmune Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 14, 2026
0.0001 0.0001
Market cap
USD 575.00
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is GBIM.US undervalued?

Graham number

The Graham number of GlobeImmune Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GlobeImmune Inc fundamental analysis

No fundamental analysis for GlobeImmune Inc yet.

GlobeImmune Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GlobeImmune Inc

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyur…

Full company profile